LP-471756

CAS No. 413605-11-5

LP-471756( —— )

Catalog No. M34320 CAS No. 413605-11-5

LP-471756 is a specific antagonist of GPR139 and inhibits LP-360924-stimulated cAMP production (IC50 = 640 nM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 29 In Stock
5MG 29 In Stock
10MG 44 In Stock
25MG 91 In Stock
50MG 145 In Stock
100MG 233 In Stock
200MG 328 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    LP-471756
  • Note
    Research use only, not for human use.
  • Brief Description
    LP-471756 is a specific antagonist of GPR139 and inhibits LP-360924-stimulated cAMP production (IC50 = 640 nM).
  • Description
    LP-471756 is a potent GPR139 antagonist with an IC50 value of 640 nM. LP-471756 inhibits LP-360924-stimulated cAMP production.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    GPR
  • Recptor
    GPR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    413605-11-5
  • Formula Weight
    329.46
  • Molecular Formula
    C19H23NO2S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 250 mg/mL (758.82 mM; Ultrasonic )
  • SMILES
    Cc1ccccc1NS(=O)(=O)c1ccc(cc1)C1CCCCC1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Vedel L, et al. Pharmacology and function of the orphan GPR139 G protein-coupled receptor. Basic Clin Pharmacol Toxicol. 2020 Jun;126 Suppl 6(Suppl 6):35-46.?
molnova catalog
related products
  • Myristyl nicotinate

    Myristyl nicotinate is an ester prodrug being developed for delivery of nicotinic acid (NIC) into the skin for prevention of actinic keratosis and its progression to skin cancer.

  • TC-O9311

    TC-O9311 is an effective agonist of GPR139 (EC50 = 39 nM in CHO-K1 cells expressing human GPR139).

  • CID 2745687

    CID 2745687 is a GPR35 antagonist that inhibited the effects at human GPR35 of cromolyn disodium and zaprinast, two agonists that share an overlapping binding site.